Travere Therapeutics Financial Statements
NASDAQ: TVTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Travere Therapeutics revenue and earnings
In fiscal 2025, Travere Therapeutics generated $490.7 million in revenue, up 110.5% from fiscal 2024, its 3rd consecutive year of revenue growth. Travere Therapeutics reported a net loss of $25.5 million, compared with a loss of $321.5 million a year earlier. Gross margin was 97.9% (up from 96.7%) and operating margin -12.8%.
Diluted earnings per share came in at -$0.29. Over the last 5 fiscal years, TVTX's revenue has grown at a 19.9% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Travere Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 490.73M | 233.18M | 145.24M | 109.46M | 131.84M | 198.32M | 175.34M | 164.25M | 154.94M | 133.59M |
| Revenue growth (YoY) | +110.45% | +60.55% | +32.69% | -16.97% | -33.52% | +13.11% | +6.75% | +6.01% | +15.98% | +33.74% |
| Cost of Revenue | 10.34M | 7.74M | 11.45M | 4.42M | 3.82M | 6.13M | 5.23M | 5.53M | 3.60M | 4.55M |
| Gross Profit | 480.39M | 225.43M | 133.79M | 105.04M | 128.02M | 192.19M | 170.10M | 158.72M | 151.33M | 129.04M |
| Operating Expenses | 543.21M | 549.26M | 521.93M | 424.85M | 327.44M | 368.36M | 307.46M | 244.29M | 208.73M | 191.81M |
| Research & Development | 206.01M | 217.50M | 244.99M | 7.50M | 201.16M | 131.77M | 140.96M | 123.76M | 78.17M | 70.82M |
| Selling, General & Admin | 337.20M | 264.12M | 265.54M | 197.52M | 126.28M | 135.80M | 128.95M | 103.65M | 101.33M | 91.94M |
| Operating Income | -62.82M | -323.83M | -388.14M | -319.81M | -199.43M | -176.16M | -137.36M | -80.04M | -53.79M | -58.21M |
| Interest Expense | 10.75M | 11.18M | 11.30M | 11.00M | 19.70M | 19.10M | 18.80M | 9.81M | 4.42M | 4.73M |
| Other Income (Expense) | 13.55M | 3.32M | 12.03M | -11.34M | -17.46M | -12.63M | -9.09M | -21.83M | -4.57M | 632.00K |
| Pretax Income | -49.27M | -320.51M | -376.11M | -331.15M | -216.88M | -188.79M | -146.45M | -101.87M | -58.36M | -57.58M |
| Income Tax | 988.00K | 120.00K | 223.00K | 313.00K | 409.00K | -19.36M | -21.00K | 811.00K | 1.37M | -9.68M |
| Net Income | -25.55M | -321.55M | -111.40M | -278.48M | -180.09M | -169.43M | -146.43M | -102.68M | -59.73M | -47.90M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | -140.86% |
| EPS (Basic) | -0.29 | -4.08 | -1.50 | -4.37 | -3.01 | -3.56 | -3.46 | -2.54 | -1.54 | -1.29 |
| EPS (Diluted) | -0.29 | -4.08 | -1.50 | -4.37 | -3.01 | -3.56 | -3.46 | -2.54 | -1.54 | -1.29 |
| Shares Outstanding (Basic) | 89.21M | 78.89M | 74.27M | 63.76M | 59.83M | 47.54M | 42.34M | 40.43M | 38.77M | 37.00M |
| Shares Outstanding (Diluted) | 89.21M | 78.89M | 74.27M | 63.76M | 59.83M | 47.54M | 42.34M | 40.43M | 38.77M | 38.29M |
| EBITDA | -2.08M | -280.27M | -349.61M | -299.09M | -186.68M | -151.58M | -116.95M | -61.37M | -35.99M | -42.08M |
| Gross Margin | 97.89% | 96.68% | 92.12% | 95.96% | 97.10% | 96.91% | 97.01% | 96.63% | 97.67% | 96.59% |
| Operating Margin | -12.80% | -138.88% | -267.24% | -292.17% | -151.27% | -88.83% | -78.34% | -48.73% | -34.72% | -43.58% |
| Net Margin | -5.21% | -137.90% | -76.70% | -254.41% | -136.60% | -85.43% | -83.51% | -62.51% | -38.55% | -35.86% |
This table shows 10 annual periods of Travere Therapeutics's income statement, from FY 2025 back to FY 2016, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow TVTX's reporting calendar. What is a income statement?